List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sarcopenia - Overview
Sarcopenia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sarcopenia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sarcopenia - Companies Involved in Therapeutics Development
Biophytis SA
Faraday Pharmaceuticals Inc
Helixmith Co Ltd
Immusoft Corp
Keren Therapeutics
MYOS RENS Technology Inc
Neurotune AG
PhaseBio Pharmaceuticals Inc
ST Pharm Co Ltd
Teijin Pharma Ltd
Sarcopenia - Drug Profiles
ARM-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVGN-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Muscle Wasting Disorders and Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit SARM1 for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Muscular Atrophy, Sarcopenia and Traumatic Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KT-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KT-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-1654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OC-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OC-504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-1023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NNMT for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclooxygenase 2 for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Cachexia, Rheumatoid Arthritis and Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium iodide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEISARM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sarcopenia - Dormant Projects
Sarcopenia - Discontinued Products
Sarcopenia - Product Development Milestones
Featured News & Press Releases
Oct 31, 2019: Biophytis files protocol amendment to optimize the SARA-INT phase 2b clinical trial for sarcopenia
Oct 04, 2019: Biophytis opens 22nd clinical site in the SARA-INT phase 2b trial of Sarconeos (BIO101) for the treatment of sarcopenia
Feb 18, 2019: Biophytis announces three oral and one poster presentations at the 2019 International Conference on Frailty and Sarcopenia Research
Dec 07, 2018: BIOPHYTIS announces one oral presentation and two poster presentations at the 11th international conference on cachexia, sarcopenia and muscle wasting
Nov 27, 2018: BIOPHYTIS to host Key Opinion Leader Meeting on the biology of Aging and its application in Neuromuscular Diseases
Sep 04, 2018: Biophytis provides enrollment update in its phase 2b SARA-OBS and SARA-INT studies of Sarconeos in sarcopenia
May 24, 2018: BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia
Mar 01, 2018: BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami
Dec 08, 2017: Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on Cachexia, Sarcopenia, and Wasting Disorders (SCWD)
Dec 04, 2017: Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium
Oct 30, 2017: BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia
Sep 25, 2017: Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia
May 11, 2017: BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia
May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial
Mar 27, 2017: Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Sarcopenia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Sarcopenia - Pipeline by Biophytis SA, H2 2019
Sarcopenia - Pipeline by Faraday Pharmaceuticals Inc, H2 2019
Sarcopenia - Pipeline by Helixmith Co Ltd, H2 2019
Sarcopenia - Pipeline by Immusoft Corp, H2 2019
Sarcopenia - Pipeline by Keren Therapeutics, H2 2019
Sarcopenia - Pipeline by MYOS RENS Technology Inc, H2 2019
Sarcopenia - Pipeline by Neurotune AG, H2 2019
Sarcopenia - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2019
Sarcopenia - Pipeline by ST Pharm Co Ltd, H2 2019
Sarcopenia - Pipeline by Teijin Pharma Ltd, H2 2019
Sarcopenia - Dormant Projects, H2 2019
Sarcopenia - Dormant Projects, H2 2019 (Contd..1), H2 2019
Sarcopenia - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Sarcopenia, H2 2019 9
Number of Products under Development by Companies, H2 2019 10
Number of Products under Development by Universities/Institutes, H2 2019 12
Number of Products by Targets, H2 2019 15
Number of Products by Stage and Targets, H2 2019 15
Number of Products by Mechanism of Actions, H2 2019 17
Number of Products by Stage and Mechanism of Actions, H2 2019 17
Number of Products by Routes of Administration, H2 2019 19
Number of Products by Stage and Routes of Administration, H2 2019 19
Number of Products by Molecule Types, H2 2019 21
Number of Products by Stage and Molecule Types, H2 2019 21

Companies Mentioned
• Biophytis SA
• Faraday Pharmaceuticals Inc
• Helixmith Co Ltd
• Immusoft Corp
• Keren Therapeutics
• MYOS RENS Technology Inc
• Neurotune AG
• PhaseBio Pharmaceuticals Inc
• ST Pharm Co Ltd
• Teijin Pharma Ltd